← Back to Search

Compound 21 for Preeclampsia

Q: What is the current capacity for enrolment in this investigation?

Affirmative. Information available on clinicaltrials.gov indicates that this trial is currently recruiting; it was initially posted on June 28th 2023 and modified most recently on July 7th 2023, with the aim of enrolling a total of 30 participants at 1 location.

Q: Are researchers still seeking participants for this investigation?

Indeed, clinicaltrials.gov does report that this experiment is recruiting participants as of July 7th 2023. Initially posted on June 28th 2021, the trial requires 30 people to be recruited from one site.

Q: Is the minimum age of participants 18 years or older for this research study?

In order to qualify for this research, individuals need to be between 18 and 45 years old. For those under the age of 18 or over 65, there are 10 trials and 50 respectively available.

Q: May I be included in this clinical investigation?

Meeting the criteria to join this research project, applicants must have pre-eclampsia and be aged between 18 and 45. Approximately 30 participants will be chosen for the trial.

Phase < 1

Recruiting

Led By Anna Reid-Stanhewicz, PhD

Research Sponsored by Anna Stanhewicz, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up a total of 1 time during the study, within ~4 weeks following enrollment

Awards & highlights

Study Summary

This trial will help identify mechanisms of long-term blood vessel damage in women who have had preeclampsia, which can lead to better clinical management of cardiovascular disease risk.

Who is the study for?

This trial is for women aged 18-45 who experienced preeclampsia between 12 weeks and 5 years ago. It's also open to those who had healthy pregnancies. Participants should not be currently pregnant, planning pregnancy, have a history of hypertension or metabolic disease before pregnancy, use tobacco, or take certain medications like antihypertensives or statins.Check my eligibility

What is being tested?

The study tests Compound 21 on the microvascular function in the skin of women post-preeclampsia. Researchers are investigating if activating angiotensin II receptors can repair blood vessel damage caused by preeclampsia and reduce future cardiovascular disease risk.See study design

What are the potential side effects?

While specific side effects of Compound 21 aren't detailed here, similar studies may involve minor reactions at the drug delivery site (skin), potential allergic responses to the compound or materials used during testing.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ a total of 1 time during the study, within ~4 weeks following enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~a total of 1 time during the study, within ~4 weeks following enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and a total of 1 time during the study, within ~4 weeks following enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in microvascular blood flow response to local compound 21 treatment measured by laser-Doppler flowmetry

Change in microvascular endothelial function following local C21 treatment compared to placebo treatment measured by laser-Doppler flowmetry

Secondary outcome measures

Angiotensin receptor expression in endothelial cells

Side effects data

From 2020 Phase 2 trial • 20 Patients • NCT04388176

17%

Urinary tract infection

Back pain

Musculoskeletal chest pain

Tremor

Tinnitus

Abdominal pain

Skin tightness

100%

80%

60%

40%

20%

Study treatment Arm

C21 200 mg

Placebo

Trial Design

1Treatment groups

Experimental Treatment

Group I: assessment of microvascular functionExperimental Treatment1 Intervention

The investigators use intradermal microdialysis to deliver compound 21 and L-NAME to the cutaneous microvasculature

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Anna Stanhewicz, PhDLead Sponsor

9 Previous Clinical Trials

350 Total Patients Enrolled

Anna Reid-Stanhewicz, PhDPrincipal InvestigatorUniversity of Iowa

Media Library

assessment of microvascular function Clinical Trial Eligibility Overview. Trial Name: NCT05937841 — Phase < 1

Pre-eclampsia Research Study Groups: assessment of microvascular function

Pre-eclampsia Clinical Trial 2023: assessment of microvascular function Highlights & Side Effects. Trial Name: NCT05937841 — Phase < 1

assessment of microvascular function 2023 Treatment Timeline for Medical Study. Trial Name: NCT05937841 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current capacity for enrolment in this investigation?

"Affirmative. Information available on clinicaltrials.gov indicates that this trial is currently recruiting; it was initially posted on June 28th 2023 and modified most recently on July 7th 2023, with the aim of enrolling a total of 30 participants at 1 location."

Answered by AI

Are researchers still seeking participants for this investigation?

"Indeed, clinicaltrials.gov does report that this experiment is recruiting participants as of July 7th 2023. Initially posted on June 28th 2021, the trial requires 30 people to be recruited from one site."

Answered by AI

Is the minimum age of participants 18 years or older for this research study?

"In order to qualify for this research, individuals need to be between 18 and 45 years old. For those under the age of 18 or over 65, there are 10 trials and 50 respectively available."

Answered by AI

May I be included in this clinical investigation?

"Meeting the criteria to join this research project, applicants must have pre-eclampsia and be aged between 18 and 45. Approximately 30 participants will be chosen for the trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Anna Stanhewicz, PhD 2023. "Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05937841.

All > Preeclampsia